Dublin, July 17, 2026 (GLOBE NEWSWIRE) — The “Radiotherapy Market – Global Forecast 2026-2032” has been added to ResearchAndMarkets.com’s offering.
The global Radiotherapy Market research report provides an in-depth assessment of clinical, technological, operational, and regional developments shaping cancer treatment. The market is projected to reach USD 10.01 billion in 2026 and grow at a CAGR of 7.73% to USD 15.72 billion by 2032. Its analysis supports strategic planning by highlighting investment priorities, capacity gaps, emerging technologies, and opportunities across established and underserved healthcare markets.
Market Overview and Growth Drivers
Radiotherapy remains a cornerstone of oncology, used alongside surgery, systemic therapy, immunotherapy, and palliative care. Demand is supported by population aging, improved screening, longer cancer survivorship, and a growing global cancer burden. Approximately 20 million new cancer cases and 9.7 million cancer deaths were recorded worldwide in 2022.
Persistent shortages of treatment equipment, brachytherapy capacity, trained professionals, and maintenance services continue to restrict access, particularly in low- and middle-income countries. The report identifies where infrastructure development, workforce investment, and scalable care models could create meaningful market opportunities while reducing operational risk.
Transformative Shifts in Radiotherapy Delivery
Clinical practice is moving toward precision techniques that improve tumor control while limiting radiation exposure to healthy tissue. Key developments include:
. Intensity-modulated and image-guided radiotherapy
. Stereotactic body radiotherapy and stereotactic radiosurgery
. Adaptive radiotherapy and proton therapy
. Brachytherapy and hypofractionated treatment regimens
Hypofractionation can reduce patient visits and increase treatment capacity when supported by appropriate protocols and quality assurance. Radiotherapy is also becoming more closely integrated with chemotherapy, targeted treatments, hormone therapy, and immunotherapy, increasing the importance of multidisciplinary planning.
Departments are adopting digital treatment planning, automated contouring, cloud collaboration, electronic quality management, and workflow optimization. Investment decisions increasingly consider equipment uptime, interoperability, cybersecurity, service support, training, patient throughput, and clinical governance.
Artificial Intelligence in Radiotherapy
Artificial intelligence is influencing imaging, auto-contouring, dose optimization, adaptive planning, quality assurance, workflow triage, and follow-up. Machine learning is also being explored for toxicity prediction, motion management, image reconstruction, radiomics, outcome modeling, and real-world evidence generation.
AI can improve consistency and reduce repetitive workloads, allowing specialists to focus on complex clinical decisions and patient care. Adoption nevertheless requires local validation, representative datasets, human oversight, cybersecurity controls, audit trails, continuous monitoring, and clear accountability. These insights enable technology leaders to evaluate solutions based on measurable clinical and operational value rather than automation alone.
Regional and Economic Group Insights
. Asia-Pacific: China, India, Japan, South Korea, and Australia are expanding advanced radiotherapy capacity, although urban and rural access remains uneven.
. Europe: Mature oncology networks support adaptive treatment, hypofractionation, clinical standardization, and research collaboration, while staffing and equipment replacement remain challenges.
. North America: The United States and Canada lead in stereotactic radiotherapy, proton therapy, adaptive treatment, clinical research, and quality assurance.
. Latin America: Brazil and Mexico are expanding capacity, but public-sector disparities and specialist shortages persist.
. Africa: Progress depends on sustainable financing, maintenance programs, training pipelines, and national cancer control planning.
. Middle East: Gulf countries are investing in specialized oncology centers, modern equipment, and multidisciplinary care pathways.
G7, NATO, and European Union markets generally lead in research, guideline development, cybersecurity, and advanced technology adoption. BRICS, ASEAN, and GCC countries present varied opportunities tied to equipment expansion, workforce training, affordable protocols, digital planning, and regional care networks. Comparative regional intelligence can inform market entry strategies and help organizations prioritize partnerships and resource allocation.
Strategic Priorities for Industry Leaders
. Assess the complete treatment ecosystem, including equipment, software, imaging, maintenance, cybersecurity, and quality assurance.
. Expand workforce pipelines for radiation oncologists, physicists, dosimetrists, therapists, nurses, engineers, and data specialists.
. Validate AI tools locally and maintain continuous clinical oversight.
. Develop hub-and-spoke networks, remote planning support, shared training platforms, and phased technology deployment.
. Reduce waiting times and financial or geographic barriers through patient-centered operating models.
Key Takeaways from This Report
. The market is forecast to reach USD 15.72 billion by 2032, growing at a 7.73% CAGR.
. Precision radiotherapy, hypofractionation, adaptive workflows, and AI are reshaping treatment delivery.
. Infrastructure, workforce, maintenance, and governance are as critical as equipment investment.
. Significant growth opportunities exist in underserved regions and expanding oncology networks.
. Sustainable adoption requires clinical validation, interoperability, quality assurance, and equitable access.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 197 |
| Forecast Period | 2026 – 2032 |
| Estimated Market Value (USD) in 2026 | $10.01 Billion |
| Forecasted Market Value (USD) by 2032 | $15.72 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Radiotherapy Market, by Radiotherapy Type
7.1. Introduction
7.2. External Beam Radiotherapy
7.2.1. X Ray Radiotherapy
7.2.2. 3D Conformal Radiation Therapy
7.2.3. Image Guided Radiotherapy
7.2.4. Intensity Modulated Radiotherapy
7.2.5. Stereotactic Radiosurgery
7.2.6. Stereotactic Body Radiotherapy
7.3. Internal Radiotherapy
7.3.1. High Dose Rate Brachytherapy
7.3.2. Low Dose Rate Brachytherapy
7.4. Intraoperative Radiotherapy
8. Radiotherapy Market, by Component
8.1. Introduction
8.2. Hardware
8.2.1. Brachytherapy Afterloaders
8.2.2. Gamma Knife Systems
8.2.3. Imaging & Guidance Systems
8.2.4. Linear Accelerators (LINACs)
8.2.5. Multileaf Collimators (MLCs)
8.2.6. Proton Therapy Systems
8.3. Service
8.3.1. Maintenance & Calibration
8.3.2. Training & Consulting
8.4. Software
8.4.1. Treatment Planning Systems
8.4.2. Dose Calculation Software
9. Radiotherapy Market, by Procedure Type
9.1. Introduction
9.2. Curative Radiotherapy
9.3. Palliative Radiotherapy
9.4. Adjuvant Radiotherapy
10. Radiotherapy Market, by Application
10.1. Introduction
10.2. Brain Tumors
10.3. Breast Cancer
10.4. Cervical Cancer
10.5. Gastrointestinal Cancer
10.5.1. Colorectal Cancer
10.5.2. Esophageal Cancer
10.5.3. Pancreatic Cancer
10.5.4. Liver Cancer
10.6. Head & Neck Cancer
10.7. Lung Cancer
10.8. Prostate Cancer
10.9. Spine Cancer
11. Radiotherapy Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
11.5. Cancer Research Institutes
12. Radiotherapy Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Radiotherapy Market, by Group
13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC
14. Radiotherapy Market, by Country
14.1. United States
14.2. China
14.3. Germany
14.4. Japan
14.5. India
14.6. United Kingdom
14.7. France
14.8. Canada
14.9. Italy
14.10. Australia
14.11. Brazil
14.12. South Korea
14.13. Mexico
14.14. Russia
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Siemens Healthineers AG
16.2. Elekta AB
16.3. Accuray Incorporated
16.4. IBA Dosimetry GmbH
16.5. Hitachi, Ltd.
16.6. Mevion Medical Systems, Inc.
16.7. ViewRay Technologies, Inc.
16.8. Mitsubishi Electric Corporation
16.9. Carl Zeiss AG
16.10. Panacea Medical Technologies Pvt. Ltd.
16.11. Agilent Technologies Inc.
16.12. BEBIG Medical GmbH
16.13. Brainlab AG
16.14. Canon Medical Systems Corporation
16.15. Cardinal Health, Inc.
16.16. CivaTech Oncology Inc.
16.17. CQ Medical
16.18. Epsilon Elektronik
16.19. GE HealthCare Technologies Inc.
16.20. Healvita Group GmbH
16.21. IntraOp Medical, Inc.
16.22. Klarity Medical Products
16.23. Koninklijke Philips N.V.
16.24. Leo Cancer Care
16.25. RaySearch Laboratories AB
16.26. RefleXion Medical Inc.
16.27. Revvity, Inc.
16.28. Sumitomo Heavy Industries Ltd.
16.29. Theragenics Corporation
16.30. Toshiba Corporation
16.31. Vision RT Ltd.
16.32. Xstrahl Limited
For more information about this report visit https://www.researchandmarkets.com/r/9y0i0p
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
